Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study.
Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Ferrillo L, Pepe A, Francalanci M, Taccetti G, Buonaurio S, Celardo A, Salvadori L, Marsicovetere G, D'Andria M, Ferrara N, Salvatore D. Carnovale V, et al. Among authors: francalanci m. J Clin Med. 2022 Feb 16;11(4):1021. doi: 10.3390/jcm11041021. J Clin Med. 2022. PMID: 35207295 Free PMC article.
Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function.
Salvatore D, Terlizzi V, Francalanci M, Taccetti G, Messore B, Biglia C, Pisi G, Calderazzo MA, Caloiero M, Pizzamiglio G, Majo F, Cresta F, Leonetti G, De Venuto D. Salvatore D, et al. Among authors: francalanci m. Respir Med. 2020 Sep;171:106073. doi: 10.1016/j.rmed.2020.106073. Epub 2020 Jul 3. Respir Med. 2020. PMID: 32846335 Free article.
[Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018].
Campagna G, Amato A, Majo F, Ferrari G, Quattrucci S, Padoan R, Floridia G, Salvatore D, Carnovale V, Puppo Fornaro G, Taruscio D, Salvatore M; Gruppo di lavoro RIFC. Campagna G, et al. Epidemiol Prev. 2021 May-Jun;45(3 Suppl 1):1-37. doi: 10.19191/EP21.3.S1.050. Epidemiol Prev. 2021. PMID: 34132083 Free article. Italian.
Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
Terlizzi V, Colangelo C, Marsicovetere G, D'Andria M, Francalanci M, Innocenti D, Masi E, Avarello A, Taccetti G, Amato F, Comegna M, Castaldo G, Salvatore D. Terlizzi V, et al. Among authors: francalanci m. Genes (Basel). 2021 Jul 29;12(8):1178. doi: 10.3390/genes12081178. Genes (Basel). 2021. PMID: 34440351 Free PMC article.
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.
Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Medio P, Ferrillo L, De Gregorio F, Francalanci M, Taccetti G, Buonaurio S, d'Ippolito M, Marsicovetere G, D'Andria M, Ferrara N, Salvatore D. Carnovale V, et al. Among authors: francalanci m. Respir Med. 2021 Nov-Dec;189:106646. doi: 10.1016/j.rmed.2021.106646. Epub 2021 Oct 12. Respir Med. 2021. PMID: 34673344 Free article.
40 results